Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials
Sign Up to like & getrecommendations! Published in 2019 at "Liver Cancer"
DOI: 10.1159/000501501
Abstract: The major histocompatibility complex on antigen-presenting cells recognizes tumorassociated antigens on the surface of cancer cells and presents the antigen to T-cell receptors on immature T cells upon migration of antigen-presenting cells to the lymph… read more here.
Keywords: hepatocellular carcinoma; oncology therapy; therapy hepatocellular; immuno oncology ... See more keywords
Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2018.08.123
Abstract: Immuno-oncology drugs that inhibit immunosuppressive receptors (CTLA4, LAG3, PD-1, TIGIT and TIM3) or activate immunostimulatory receptors (4-1BB, GITR, ICOS and OX40) are emerging as promising therapeutics for cancer patients (1-3). PD-1 (CD279 or PDCD1), consisting… read more here.
Keywords: oncology therapy; combination immuno; immuno oncology; cancer ... See more keywords